Orchard Therapeutics
↗London, United Kingdom
Orchard Therapeutics is a global leader in the field of hematopoietic stem cell (HSC) gene therapy. The company is dedicated to transforming the lives of patients with rare and devastating genetic diseases through the development of curative, one-time gene therapies. Their proprietary platform involves harvesting a patient's own blood stem cells, genetically modifying them outside the body to correct a missing or faulty gene, and reinserting them into the patient.
In early 2024, the company was acquired by Kyowa Kirin to serve as a global hub for genetic medicine. Orchard's portfolio includes the first and only FDA-approved gene therapy for metachromatic leukodystrophy (MLD), marking a significant milestone in the commercialization of advanced medicinal products.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$10M-$50M (pre-acquisition estimate)
Founded:2015
Ownership:subsidiary
Status:operating
FUNDING
Stage:Acquired
Total Raised:$440M
Investors:Kyowa Kirin, Foresite Capital, Citadel, Perceptive Advisors, Deerfield Management, RA Capital Management
STOCK
Exchange:Formerly NASDAQ
Ticker:ORTX (Delisted)
Market Cap:$477.6M (at acquisition)
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved
Modalities:HSC Gene Therapy, Lentiviral Vector, Ex vivo gene therapy
Active Trials:12
Trial Phases:Phase 1: 4 | Phase 2: 5 | Phase 3: 2 | Phase 4: 1
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Kyowa Kirin Co., Ltd.
Acquired By:Kyowa Kirin Co., Ltd. (2024-01-01)
Key Partnerships:San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), GlaxoSmithKline (GSK) - Portfolio acquisition in 2018, Pharming Group N.V. - OTL-105 development
COMPETITION
Position:Leader
Competitors:Bluebird Bio, Rocket Pharmaceuticals, Beam Therapeutics, Passage Bio
LEADERSHIP
Key Executives:
Bobby Gaspar, M.D., Ph.D. - CEO
Frank Thomas - President & COO
Leslie Meltzer, Ph.D. - Chief Medical Officer
Scientific Founders:Bobby Gaspar, Adrian Thrasher, Donald Kohn, Andrea Spezzi
Board Members:Masashi Miyamoto (Kyowa Kirin CEO), Takeyoshi Yamashita
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Orchard Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.